Clinical trial of intranasal live-attenuated COVID-19 vaccine begins in U.K.
Codagenix and the Serum Institute of India have begun a phase I clinical trial of COVI-Vac in London after receiving regulatory approval from the Medicines and Healthcare Products Regulatory Agency in the U.K. Read More
Intellia demonstrates efficacy of gene therapy in preclinical models
Intellia Therapeutics has demonstrated that physiological protein levels of human alpha-1 antitrypsin in nonhuman primates can be achieved following a single administration of its in vivo gene therapy. Read More
Locanabio nabs $100M in series B round for RNA-targeting gene therapies
Locanabio has raised $100 million in a series B funding round to further develop its novel RNA-targeting platform and to advance multiple programs to investigational new drug-enabling studies in 2021. Read More
Various updates for Pfizer, BioNTech COVID-19 vaccine post-EUA
Various announcements and updates regarding the Pfizer-BioNTech COVID-19 vaccine were made during the weekend and on Monday, December 14. These included publishing immune data from the phase I trial in Germany, new recommendations from Health Canada, and an independent U.S. Centers for Disease Control and Prevention committee recommending the vaccine for use. Read More
ImmunityBio COVID-19 oral vaccine effective in nonhuman primates
ImmunityBio's COVID-19 vaccine candidate has been shown to protect nasal and lung airways of nonhuman primates against SARS-CoV-2 in preclinical studies. Read More
Reports: White House tells FDA to approve COVID-19 vaccine
The White House ordered the U.S. Food and Drug Administration (FDA) Commissioner Dr. Stephen Hahn to ensure that the FDA granted an emergency use authorization for Pfizer-BioNTech's COVID-19 vaccine by the end of the day on December 11 or he should resign, according to multiple published reports. Read More
Sanofi, GSK COVID-19 vaccine program delayed by responses in elderly
Sanofi and GlaxoSmithKline (GSK) are delaying their adjuvanted recombinant protein-based COVID-19 vaccine program to improve the vaccine's immune response in older adults. Read More
Pfizer, BioNTech's COVID-19 vaccine shows 95% efficacy
In a trial of more than 40,000 participants, Pfizer-BioNTech's COVID-19 vaccine showed a 95% efficacy against the SARS-CoV-2 virus, according to results published in the New England Journal of Medicine on December 10. Read More
AstraZeneca to test Russian Sputnik V vaccine
AstraZeneca said it will use one of the components of the Sputnik V vaccine, Russia's COVID-19 vaccine, in its own clinical trials for a COVID-19 vaccine. The component was offered by the Russian Direct Investment Fund (Russia's sovereign wealth fund) and the Gamaleya Center. Read More
Twist offers new gene fragments to the synthetic biology market
Twist Bioscience has launched its new clonal-ready gene fragments. The gene fragments, with and without adapters, can be used to rapidly build constructs and minimize the time and cost of screening for clones. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
